Antares Seals License, Asset Purchase Agreements With Ferring

Antares Pharma (Antares) has entered into a license and an asset purchase agreement with Ferring International Center. Under the terms of the exclusive license agreement Ferring obtained rights to certain intellectual property relating to Antares’ proprietary transdermal gel delivery technology.

Reportedly, upon closing of the asset purchase agreement Ferring is expected to purchase research equipment and assume responsibility for Antares’ leased development facility in Allschwil, Switzerland.

The company said that these agreements will have no impact on Antares’ current licenses, the transdermal clinical pipeline, or marketed products including Anturol LibiGel, Nestorone, and Elestrin. Financial terms of the agreements which consist of upfront payments and milestones were not disclosed.

Paul Wotton, president and CEO of Antares, said: “We are pleased that we have expanded our strong partnership with Ferring to include our transdermal gels and delighted that Ferring has agreed to retain a significant majority of our employees at our Allschwil facility.”